Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively

Transfusion

Volumn 58, Issue 9, 2018, Pages 2202-2207

  Eickmann, Markus ^a   Gravemann, Ute ^b   Handke, Wiebke ^b   Tolksdorf, Frank ^c   Reichenberg, Stefan ^c   Müller, Thomas H ^b   Seltsam, Axel ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Institute Springe   (Germany)

^c MacoPharma International GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLENE BLUE; THROMBOCYTE CONCENTRATE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; EBOLAVIRUS; LIGHT; LIMIT OF DETECTION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PLASMA; ULTRAVIOLET C RADIATION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS LOAD; ANIMAL; BLOOD; CHLOROCEBUS AETHIOPS; COMPARATIVE STUDY; CORONAVIRUS INFECTION; DRUG EFFECT; EBOLA HEMORRHAGIC FEVER; HUMAN; ISOLATION AND PURIFICATION; RADIATION RESPONSE; THROMBOCYTE; ULTRAVIOLET RADIATION; VERO CELL LINE; VIREMIA; VIROLOGY;

ANIMALS; BLOOD PLATELETS; CERCOPITHECUS AETHIOPS; CORONAVIRUS INFECTIONS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; LIGHT; METHYLENE BLUE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PLASMA; ULTRAVIOLET RAYS; VERO CELLS; VIREMIA; VIRUS INACTIVATION;

EID: 85046463418     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14652     Document Type: Article

References (32)

1. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49 Suppl 2:1S-29S
2. Stramer SL. Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014;9:30-6
3. Rabaan AA. Middle East respiratory syndrome coronavirus: five years later. Exp Rev Resp Med 2017;11:901-12
4. Rha B, Rudd J, Feikin D, et al. Update on the epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, and guidance for the public, clinicians, and public health authorities—January 2015. MMWR Morb Mortal Wkly Rep 2015;64:61-2
5. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76
6. World Health Organization. WHO: Ebola situation report 12 May 2016 [cited 2018 Apr 16]. Available from: http://www.who.int/iris/handle/10665/206313
7. Seltsam A, Müller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013;162:442-54
8. Mohr H, Steil L, Gravemann U, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009;49:2612-24
9. Seltsam A, Müller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011;38:43-54
10. Kim S, Handke W, Gravemann U, et al. Mitochondrial DNA multiplex real-time polymerase chain reaction inhibition assay for quality control of pathogen inactivation by ultraviolet C light in platelet concentrates. Transfusion 2018;58:758-65
11. Douki T, Laporte G, Cadet J. Inter-strand photoproducts are produced in high yield within A-DNA exposed to UVC radiation. Nucleic Acids Res 2003;31:3134-42
12. Seghatchian J, Struff WG, Reichenberg S. Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011;38:55-64
13. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003;43:1322-9
14. Mohr H, Lambrecht B, Selz A. Photodynamic virus inactivation of blood components. Immunol Invest 1995;24:73-85
15. Seghatchian J, Walker WH, Reichenberg S. Updates on pathogen inactivation of plasma using Theraflex methylene blue system. Transfus Apher Sci 2008;38:271-80
16. Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002;16:61-6
17. Faddy HM, Fryk JJ, Prow NA, et al. Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 2016;56:1548-55
18. Fryk JJ, Marks DC, Hobson-Peters J, et al. Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light. Transfusion 2017;57:2677-82
19. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Gesamtnovelle 2005 mit Richtlinienanpassung 2010 ed. Köln: Deutscher Ärzte-Verlag; 2010
20. Eriksson L, Shanwell A, Gulliksson H, et al. Platelet concentrates in an additive solution prepared from pooled buffy coats. In vivo studies. Vox Sang 1993;64:133-8
21. Gulliksson H, Larsson S, Kumlien G, et al. Storage of platelets in additive solutions: effects of phosphate. Vox Sang 2000;78:176-84
22. Steinmann E, Gravemann U, Friesland M, et al. Two pathogen reduction technologies—methylene blue plus light and shortwave ultraviolet light—effectively inactivate hepatitis C virus in blood products. Transfusion 2013;53:1010-8
23. Castro E, Girones N, Guerrero N, et al. The effectiveness of UVC pathogen inactivation system on reducing the Trypansosoma cruzi and Leishmania infantum burden in platelets. Vox Sang 2008;95:290
24. Castro E, González LM, Rubio JM, et al. The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion 2014;54:2207-16
25. Reichenberg S, Gravemann U, Sumian C, et al. Challenge study of the pathogen reduction capacity of the THERAFLEX MB-Plasma technology. Vox Sang 2015;109:129-37
26. Gironés N, Bueno JL, Carrión J, et al. The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma. Vox Sang 2006;91:285-91
27. Woolhouse ME, Haydon DT, Antia R. Emerging pathogens: the epidemiology and evolution of species jumps. Trend Ecol Evol 2005;20:238-44
28. Cap AP, Pidcoke HF, Keil SD, et al. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 2016;56 Suppl 1:S6-15
29. Ji X, Olinger GG, Aris S, et al. Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 2005;86:2535-42
30. Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis 2016;62:477-83
31. Li J, Duan HJ, Chen HY, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis 2016;42:34-9
32. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399-411